



Berkshire West Area Prescribing Committee (BWAPC)

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Eslicarbazepine (Zebinix®)
Indication under review	Epilepsy
Policy No:	APC 087
Date of Issue:	September 2014
Review Date:	September 2017
Policy Statement: Eslicarbazepine (Zebinix®) is recommended as adjunctive treatment for patients with partial onset seizures with or without secondary generalisation.	
Traffic Light Status	Amber
Key Points considered: <ul style="list-style-type: none"> • Treatment should always be initiated by an epilepsy specialist working within a tertiary care setting. • For use when other adjunctive treatments are not effective. • Treatment is as recommended within NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (Published January 2013, modified Dec 2013). 	
References: NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (Published January 2013, modified Dec 2013).	
Date taken to APC:	3 rd September 2014
Date Ratified by MMC on Behalf of the Board:	8 th October 2014